anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: Three-dimensional surgical planning (3-DSP) is becoming commonplace in the management of benign and malignant disease for oral and maxillofacial surgery practice within the last decade. Surgeons utilize a virtual "wrap" to preoperatively delineate and define maxillofacial tumor resection margins. The investigators hypothesized that the use of a wrap is a predictable method to obtain negative bony margins.
METHODS: The investigators implemented a retrospective chart review. The sample was composed of patients over the age of 18 treated at John Peter Smith Health Network and Parkland/UT Southwestern Medical Center who obtained 3-DSP for the pathology of the head and neck, involving the bone, with a virtual wrap utilized for bony margins. The proportion of cases was calculated, descriptive statistics were reported, and binomial exact calculation was performed for confidence intervals. The primary variable analyzed was bony margin status on final histopathology, involved or uninvolved, based on the pathology report.
RESULTS: The sample was composed of 39 cases, one of which was excluded due to aborting the preplanned 3-DSP. Of the 38 included cases, one had involved bony margin on final histopathology (2.6%; 95% confidence limits, 0.1%, 13.8%). There were 16 malignant cases (42%) and 22 benign cases (58%). When stratified by pathology, 1 out of the 16 malignant cases (6.3%; 95% confidence interval, 0.2%, 30%) and 0 out of the 22 benign cases (95% confidence interval, 0%, 15.4%) had an involved bony margin on final histopathology.
CONCLUSION: The results of this preliminary study suggest three-dimensional surgical planning with wrap margins is a predictable method to obtain negative bony margins in benign and malignant disease of the maxillofacial complex. Further studies will focus on compiling prospective data to solidify the accuracy and predictability of using a wrap to obtain negative bony margins.
Adverse drug reactions that have been first identified during post-marketing experience with itraconazole (all formulations) are listed in the table below. Because these reactions are reported voluntarily from a population of uncertain size, reliably estimating their frequency or establishing a causal relationship to drug exposure is not always possible.

There is limited information on the use of itraconazole during pregnancy. Cases of congenital abnormalities including skeletal, genitourinary tract, cardiovascular and ophthalmic malformations as well as chromosomal and multiple malformations have been reported during post-marketing experience. A causal relationship with itraconazole has not been established (see CLINICAL PHARMACOLOGY: Special Populations, CONTRAINDICATIONS, WARNINGS, and PRECAUTIONS: Drug Interactionsfor more information). 

To report SUSPECTED ADVERSE REACTIONS, contact Amneal Pharmaceuticals at 1-877-835-5472 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
BACKGROUND: Proteoglycans are important tumor microenvironment extracellular matrix components. The regulation of key proteoglycans, such as decorin (DCN), by miRNAs has drawn attention since they have surfaced as novel therapeutic targets in cancer. Accordingly, this study aimed at identifying the impact of miR-181a in liver cancer and its regulatory role on the extracellular matrix proteoglycan, DCN, and hence on downstream oncogenes and tumor suppressor genes.
RESULTS: DCN was under-expressed in 22 cirrhotic and HCC liver tissues compared to that in 11 healthy tissues of liver transplantation donors. Conversely, miR-181a was over-expressed in HCC liver tissues compared to that in healthy liver tissues. In silico analysis predicted that DCN 3'UTR harbors two high-score oncomiR-181a binding regions. This was validated by pmiRGLO luciferase reporter assay. Ectopic miR-181a expression into HuH-7 cells repressed the transcript and protein levels of DCN as assessed fluorometrically and by western blotting. DCN siRNAs showed similar results to miR-181a, where they both enhanced the cellular viability, proliferation, and clonogenicity. They also increased Myc and E2F and decreased p53 and Rb signaling as assessed using reporter vectors harboring p53, Rb, Myc, and E2F response elements. Our findings demonstrated that miR-181a directly downregulated the expression of its direct downstream target DCN, which in turn affected downstream targets related to cellular proliferation and apoptosis.
CONCLUSION: To our knowledge, this is the first study to unveil the direct targeting of DCN by oncomiR-181a. We also highlighted that miR-181a affects targets related to cellular proliferation in HCC which may be partly mediated through inhibition of DCN transcription. Thus, miR-181a could be a promising biomarker for the early detection and monitoring of liver cancer progression. This would pave the way for the future targeting of the oncomiR-181a as a therapeutic approach in liver cancer, where miR-181a-based therapy approach could be potentially combined with chemotherapy and immunotherapy for the management of liver cancer.
Patients who are diagnosed with healthy control. Blood will be collected once every 6 months for up to 3 years.
An implantable infection shield and system for drug delivery in vascular tissue includes a relatively non-biodegradable porous linked fibrous biomaterial which controls and directs cell growth and angiogenesis from adjacent vascular tissue into the implant. Infection shield embodiments stimulate cell growth and angiogenesis from adjacent vascular tissue which effectively blocks passage of pathogenic microorganisms along percutaneously implanted objects. In embodiments for drug delivery, a reservoir of the same biomaterial may contain either (1) a cell culture system enclosed within a porous sealable interior chamber or (2) a biodegradable matrix in which one or more drugs are dispersed. After implantation of a reservoir of the first embodiment in an organism, cultured cells obtain food and oxygen via diffusion in tissue fluid through the porous walls of the interior chamber, while metabolic products, including drugs, diffuse away from the cell culture in an analogous manner. In a reservoir of the second embodiment, a biodegradable matrix substantially fills the pores (voids), and progressive dissolution of the matrix releases one or more drugs into surrounding tissue fluid. Reservoirs of either embodiment comprise a plurality of voids of a predetermined size effective for stimulating angiogenesis from the surrounding vascular tissue into at least a portion of the reservoir. The reservoir thus acts to couple a source: of drugs to the circulatory system of the organism.
Atrial fibrillation (AF) is the most common heart rhythm abnormality. It affects 1 in 100 people. It can cause unpleasant symptoms of palpitation, shortness of breath and in some can cause heart failure or stroke. AF is triggered by abnormal electrical signals originating both in the pulmonary veins (PV), the veins that drain blood from the lungs into the heart, and in the rest of the left atrium, the heart chamber that the PVs drain into. AF can be successfully treated by a procedure called catheter ablation. This involves passing a wire up the vein at the top of the leg and delivering radiofrequency energy to the atrial tissue. This renders that tissue electrically inert. For many years this procedure has been guided by 3D cardiac mapping systems capable of showing the position of the catheters in the heart and recording their electrical signals. By doing a series of radiofrequency treatments around the mouth of the PVs it is possible to electrically isolate them so that PV signals cannot start or sustain AF. This leaves the left atrial signals untreated and limits the success of the procedure to 50%. To date clinicians have tried numerous ways to identify these remaining left atrial signals, but so far, their efforts have not improved the outcomes of ablation over just isolating the PVs alone (50% success rate). STAR Apollo Mapping System is an FDA cleared mapping technology that can analyze the signals collected during the ablation procedure on the 3D mapping system and give the physician further insight into the AF activation patterns which may assist them in identifying areas responsible for maintaining AF. The STAR Apollo Mapping System system allows clinicians, after treating the PVs, to collect data from the atria during clinical AF procedures using standard FDA cleared catheters and devices. This study aims to examine the impact of the STAR Apollo Mapping System on procedural and acute outcomes in a multicenter observational study.
The invention discloses an auxiliary acupuncture positioning system and method based on a three-dimensional human body model. The system consists of head display equipment, a three-dimensional human body model, a human body gesture recognition module, a human body model alignment module, an acupuncture point positioning module and a user interaction module. The head display device captures images of the real environment and three-dimensional structure information thereof. The three-dimensional human body model is a virtual model, and virtual acupuncture points are marked on the three-dimensional human body model. The human body posture recognition module predicts a posture of the patient from the captured image. The mannequin alignment module aligns the predicted patient pose with the virtual mannequin using a numerical optimization algorithm. The acupuncture point positioning module converts the positions of the virtual acupuncture points to the real patient body according to the alignment relation. The user interaction module provides a user interaction mode, so that a user can see the body of a real patient and can see a virtual human body model and acupuncture points. The system enables an acupuncture operator to find acupuncture points more accurately and conveniently, and improves treatment effect.
Methods: 422 adults with complex chronic conditions will be identified upon admission to a university-based acute care general medical service. Patients will be asked to identify a CarePartner (CP) living outside their household; CPs will be spouses, adult children, and others in their social network willing to play an active role in their transition support. Patients will be randomized to the intervention or usual care. Intervention patients will receive automated assessment and behavior change calls, and their CPs will receive structured feedback and advice following each assessment. Patients' clinical team will have access to patients' assessment results via the web, will receive automated reports about urgent health problems, and will be able to communicate asynchronously with patients and CPs using a secure web page and a specially designed voicemail service. Patients will complete surveys at baseline, 30- and 90- days post discharge; utilization data will be obtained from hospital records. CPs and clinicians will be interviewed to evaluate intervention effects on processes of self-care support, caregiver stress and communication, and the intervention's potential for broader implementation. The primary outcome will be 30 day readmission rates; 2ndary outcomes include functional status, self-care behaviors, and mortality risk.
ESP block will be performed. US probe will be placed longitudinally 2-3 cm lateral to the L3 transverse process. Erector spinae muscle will be visualized on the hyperechoic transverse process. The block needle (100 mm, 22G) will be inserted cranio-caudal direction and then for correction of the needle 2 ml saline will be injected deep into the erector spinae muscle fascia. Following confirmation of the correct position of the needle 30 ml 0.25% bupivacaine will be administered for the block.
This is a dose escalation study of a new radiopharmaceutical agent, 153Sm-DOTMP. Eligible participants will have osteosarcoma metastatic to bone, other solid tumors with bone metastases, or an unresectable localized osteosarcoma. Because of anticipated prolonged myelosuppression, participants will have a peripheral blood stem cell harvest. They will then be treated with 2 doses of 153Sm-DOTMP given 7 days apart. Twenty-four days after the initial dose, stem cells will be reinfused if needed. The first three cohorts of participants will receive only radiopharmaceutical. If Dose Level 3 is not the maximally tolerated dose (MTD), subsequent dose levels will include external beam radiotherapy, administered beginning on Day 15. The dose of external beam radiotherapy will be determined by dosimetry studies performed after each administration of study agent, and will be targeted to a tumoricidal dose of radiation. All participants will have disease re-evaluation 30 days following completion of all study treatments, and then at 4, 6, 8, and 12 months, unless they experience disease progression.
Tape will be applied to the biceps muscle of the nondominant arm from approximately the shoulder to the elbow for up to 72 hours. The placebo KT group will have 0% tension.
A process for producing an effervescent granulate containing at least one solid, crystalline, edible organic acid, in particular citric acid, and at least one alkaline or alkaline earth metal carbonate that breaks down into CO2 by reacting with the organic acid in an aqueous solution. To form a first coating layer with a first powdered coating mass containing at least one alkaline or alkaline earth metal carbonate and adhering to a binding layer formed by the reaction of acid and carbonate at the surface layer of the acid crystal, if necessary in a vacuum mixer, part of the total amount of acid and part of the alkaline and/or alkaline earth metal carbonate(s) of the first coating mass are dissolved and made to react with each other in a solvent for the acid, such as water, alcohol or a mixture thereof. The prereactive solution thus obtained is then applied on the acid crystals and exposed, after the first coating layer is formed, to at least one additional solid powdered coating mass, during an additional reaction step; it is then made to react by intensive mixing with the previous coating mass, formed during the previous reaction step and humidified by the constitutional water produced during reaction, thus forming at least one additional coating layer. A final drying step concludes the formation of the coatings. To the acid crystals reticulated with the prereactive solution a salt is applied that is able to irreversibly link water in the total complex, and L-carnitine is added to the coated acid crystals. An effervescent granulate thus produced and its use are also disclosed.
En- masse retraction using NiTi closed coil springs rendering 200 g/side were employed following first premolars extraction and insertion of buccal TADs to provide maximum anchorage. Retraction was done along with the application of LLLT till the end of retraction.
NEW MATERIAL:25-Hydroxy-26,27-dimethylvitamin D3. USE:A remedy for Ca dysbolism and osteoporosis. It has powerful vitamin D3 activity with reduced toxicity. PREPARATION:The reaction of 3beta-tetrahydropyranyloxy-26,27-dinorcholest-5- ene-25-oic acid methyl ester with halogenated magnesium ethyl or ethyl lithium is effected, the product is hydrolyzed to give 26,27-dimethylcholest-5-ene-3beta,25- diol. The compound is aclated in the 3beta-hydroxyl and a double bond is introduced between carbon atoms in the 7 and 8-positions, further the acyl group in the 3beta-position is hydrolyzed to give 26,27-dimethylcholesta-5,7-diene-3beta,25-diol. Then, the product is irradiated with ultraviolet rays to give the compound of the formula.
PCT No. PCT/JP92/00983 Sec. 371 Date Feb. 14, 1994 Sec. 102(e) Date Feb. 14, 1994 PCT Filed Jul. 31, 1992 PCT Pub. No. WO93/03747 PCT Pub. Date Mar. 4, 1993.The invention provides a stabilized IL-1 alpha  medicinal composition comprising an IL-1 alpha  active substance, serum albumin and a saccharide. The medicinal composition of the invention has very desirable characteristics in terms of the stability of its active ingredient IL-1 alpha  active substance, rendering it stable throughout its processing into various dosage forms, such as freezing and freeze-drying, and for a long time after production under the usual storage conditions, thus being of great utility value in the relevant field.
Compositions derived from traditional Chinese herbal medicines, medicinal plants and extracts thereof, are provided for the prevention and treatment of cancers especially cancer of the lung, esophagus, stomach, oral cavity and prostate as well as for treating  Helicobacter pylori  infection. The compositions of the invention are obtained through specific techniques and have demonstrated efficacy for chemoprevention of cancers of the lung, esophagus, stomach, and the oral cavity as well as exhibiting in vitro activity against prostate cancer and leukemic cell lines. The compositions are useful as adjuncts to conventional surgery or radiotherapy treatments in patients with esophageal cancer. The compositions are effective as a treatment for  H. pylori  infection. Currently, there is no effective chemopreventive agent for these cancers. The current invention addresses a special need in cancer control. Preferred compositions of the invention contain the herbal ingredients  Sophora tonkinensis, Polygonum bistorta, Prunella vulgaris, Sonchus brachyotus, Dictamnus dasycarpus  Turcz, and  Dioscorea bulbifera.
Retinopathy of prematurity (ROP) has been widely acknowledged to be the primary cause of preventable childhood blindness in developing countries. However, the procedure for screening is extremely painful. In this study, we will attempt to relieve the pain experienced by these babies using breast milk alone or in combination with oral paracetamol. This randomized control trial study will be conducted with the aim to assess the efficacy of Expressed Breast Milk Alone or in Combination with Paracetamol in Reducing Pain during ROP Screening. All preterm neonate who undergone ROP screening will be the study population. A total of 60 preterm neonates will be randomized into three groups: (Group A - control group = 20, Group B - breast milk group = 20, and Group C - oral paracetamol + breast milk = 20). Group A will get current care as per institutional protocol, Group B received 2 ml expressed breast milk (EBM) through a sterile syringe orally 2 min prior to procedure, Group C received syrup paracetamol, 15 mg/kg 30 min prior to procedure and EBM as in Group B. Pain experienced was measured by the premature infant pain profile (PIPP) score 20 s prior, during and 2 min after procedure. All procedures were video recorded. The Ophthalmologist and analyzer both will be blinded to the intervention. Results will be incorporated after enrollment
The invention discloses a polypeptide RVA6 with nervous system injury resistance and neuroprotection and application thereof. The amino acid sequence of the RVA6 polypeptide is shown as SEQ ID NO. 1. The polypeptide RVA6 is a polypeptide compound with a new structure for stabilizing the DR region of NKA alpha 1 subunit and identified by commercial synthesis and activity. The polypeptide RVA6 has low toxicity and good application prospect. The polypeptide RVA6 can improve the cell survival rate of the PD in-vitro model under a lower concentration, inhibit the generation of active oxygen, relieve autophagy disorder and iron death process, and has the function of resisting nerve injury. The polypeptide RVA6 can improve the behavioral disorder and pathological characteristics of PD and depression model animals, has neuroprotection, is easy to synthesize and is easy to prepare in a large scale.
Do not put too much Spotex on your skin. You will not get rid of the acne any quicker. If you put on too much, your skin may become irritated and red. Some peeling or discomfort could also occur. If any of these happen, use Spotex once a day in the evening until they have gone. Then apply Spotex twice a day as you did previously. If the effects continue or are causing you a lot of discomfort, stop using the product and ask your doctor or pharmacist for advice.   
In the rare event that you accidentally swallow any of this product, seek medical advice.
Subjects will receive ten doses of G-CSF at a dose of 5 mcgm/kg daily Monday through Friday for the first two weeks of the trial. All patients will also receive trastuzumab at 4 mg/kg week 1, and 2 mg/kg week 2 during the first two weeks of the trial. All patients will then receive 12 weeks of trastuzumab at 2 mg/kg IV weeks 3 through 14, vinorelbine at 25 mg/m2 IV weekly weeks 3,4,6,7,9,10,12,13 and G-CSF at 5 mcgm/kg SQ daily Monday through Friday weeks 3-14.
The dialysis concentrate has the components of the acid concentrate components in a vessel in a high concentration. The dialysis concentrate is a sludge of at least one powder or granule component. The other components of the concentrate are held while dissolved in water or a number of powder or granule components are in a sludge, and the other components of the acid concentrate components are dissolved in water. The basic component of the dialysis concentrate is dry, and stored in a separate vessel. An independent claim is also included for an apparatus to prepare the dialysis concentrate, with a vessel (4) to hold components in a sludge. It has a batch vessel (5), with a connecting tube between the vessels (4,5). It has a water feed (1) and outlet (21), and a pump (11) for the recirculation of the dialysis concentrate and water, to dissolve the solid components wholly and homogeneously in an even distribution.
Apigenin (API) is a natural flavonoid compound with antioxidant, anti fibrotic, anti-inflammatory and other effects, but there is limited research on the effect of API on liver fibrosis. This study aims to explore the effect and potential mechanism of API on liver fibrosis induced by CCl4 in mice. The results indicate that API reduces oxidative stress levels, inhibits hepatic stellate cell (HSC) activation, and exerts anti liver fibrosis effects by regulating the PKM2-HIF-1α pathway. We observed that API alleviated liver tissue pathological damage and collagen deposition in CCl4 induced mouse liver fibrosis model, promoting the recovery of liver function in mice with liver fibrosis. In addition, the API inhibits the transition of Pyruvate kinase isozyme type M2 (PKM2) from dimer to tetramer formation by regulating the EGFR-MEK1/2-ERK1/2 pathway, thereby preventing dimer from entering the nucleus and blocking PKM2-HIF-1α access. This change leads to a decrease in malondialdehyde (MDA) and Catalase (CAT) levels and an increase in glutathione (GSH), superoxide dismutase (SOD), glutathione peroxidase (GSH-PX) levels, as well as total antioxidant capacity (T-AOC) in the liver of liver fibrosis mice. At the same time, API downregulated the expression of α-smooth muscle actin (α-SMA), Vimentin and Desmin in the liver tissue of mice with liver fibrosis, inhibited the activation of HSC, and reduced collagen deposition. These results indicate that API can inhibit HSC activation and alleviate CCl4 induced liver fibrosis by inhibiting the PKM2-HIF-1α pathway and reducing oxidative stress, laying an important foundation for the development and clinical application of API as a novel drug for treating liver fibrosis.